| 1 |
35179349 | Depleting Tumor Infiltrating B Cells to Boost Antitumor Immunity with Tumor Immune-Microenvironment Reshaped Hybrid Nanocage. | 2022 Mar 22 |
1 |
| 2 |
34018029 | Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. | 2021 Jul |
1 |
| 3 |
34858727 | Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma. | 2021 |
1 |
| 4 |
32228672 | Inhibition of effector B cells by ibrutinib in systemic sclerosis. | 2020 Mar 30 |
1 |
| 5 |
30940906 | CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages. | 2019 Oct |
1 |
| 6 |
28972595 | Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. | 2018 Apr |
1 |
| 7 |
29496671 | BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. | 2018 May 3 |
1 |
| 8 |
30209121 | B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma. | 2018 Oct 25 |
1 |
| 9 |
26942065 | Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells. | 2016 |
1 |
| 10 |
27602755 | Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. | 2016 Oct 4 |
1 |